Alvotech Ordinary Shares (ALVO) is a publicly traded Healthcare sector company. As of May 21, 2026, ALVO trades at $3.30 with a market cap of $1.01B and a P/E ratio of 0.00. ALVO moved +0.91% today. Year to date, ALVO is -32.65%; over the trailing twelve months it is -66.26%. Its 52-week range spans $3.03 to $13.70. Analyst consensus is neutral with an average price target of $4.67. Rallies surfaces ALVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alvotech Q1 revenues drop 20% to $105.9m, secures FUJIFILM supply deal: Alvotech reported Q1 revenues of $105.9m versus $132.8m a year earlier, with adjusted EBITDA of $24.4m and 57% gross margin following production slowdowns. It filed EMA applications for AVT16/80, started an AVT29 study for Eylea, secured a FUJIFILM U.S. supply deal, guiding 2026 revenues of $650m–$700m with EBITDA of $180m–$220m.
| Metric | Value |
|---|---|
| Price | $3.30 |
| Market Cap | $1.01B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.70 |
| 52-Week Low | $3.03 |
| Volume | 64 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover ALVO: 0 strong buy, 1 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $4.67.